Collectively, our findings reveal a novel role of STAT6 in ALL cell sensitivity to Ara-C and demonstrate the effectiveness of multiple strategies against STAT6, offering a plausible modality to treat ALL via STAT6 targeting. This evidence concerns the gene STAT6 and acute lymphoblastic leukemia.